Case-control study links splenomegaly to elevated metabolic and inflammatory markers in chronic schizophrenia

A case-control study analyzed 426 patients with chronic schizophrenia (165 with splenomegaly, 261 without) to identify risk factors for splenomegaly and explore associations among metabolic-immunoinflammatory pathways, psychiatric symptoms, and splenomegaly. The primary outcome was identifying risk factors, with secondary outcomes examining these pathway associations. The study setting and specific intervention or exposure were not reported, with the comparator being the non-splenomegaly group.

The main finding was that the splenomegaly group had significantly higher levels of lipoprotein(a), cholesterol, triglycerides, HbA1c, CRP, IL-6, and β2-microglobulin compared to the group without splenomegaly. The result was reported as statistically significant (p < 0.05 implied), but exact effect sizes, absolute numbers, and confidence intervals were not provided. The direction of association was higher for all measured markers in the splenomegaly group.

Safety and tolerability data were not reported. Key limitations include the observational case-control design, which precludes causal inference, and the lack of reported effect sizes and absolute numbers. Funding sources and conflicts of interest were also not reported. The practice relevance is cautiously framed as potentially helping to optimize somatic monitoring strategies by highlighting associated metabolic and inflammatory markers in patients with chronic schizophrenia and splenomegaly.